Interferon alpha-2a plus ribavirin 1,000/1,200 mg versus interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial.

Huber, M; Weber, R; Oppliger, R; Vernazza, P; Schmid, P; Schönbucher, P; Bertisch, B; Meili, D; Renner, E L

Huber, M; Weber, R; Oppliger, R; Vernazza, P; Schmid, P; Schönbucher, P; Bertisch, B; Meili, D; Renner, E L.

Affiliation

Huber M; Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH-8091 Zurich, Switzerland. milo.huber@usz.ch

Infection ; 33(1): 25-9, 2005 Feb.

Article in En | MEDLINE | ID: mdl-15750756

Subject(s)

Antiviral Agents/administration & dosage; Hepatitis C, Chronic/drug therapy; Interferon-alpha/administration & dosage; Ribavirin/administration & dosage; Antiviral Agents/adverse effects; Antiviral Agents/therapeutic use; Drug Therapy, Combination; Female; Hepatitis C, Chronic/complications; Humans; Interferon alpha-2; Interferon-alpha/adverse effects; Interferon-alpha/therapeutic use; Male; Recombinant Proteins; Ribavirin/adverse effects; Ribavirin/therapeutic use; Substance Abuse, Intravenous/complications

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Ribavirin / Interferon-alpha / Hepatitis C, Chronic Type of study: Clinical_trials / Guideline Limits: Female / Humans / Male Language: En Journal: Infection Year: 2005 Document type: Article Affiliation country: Switzerland Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links